Nuzenio

Evommune Reports Second

Evommune Reports Second news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 8 latest news signals 5 publisher sources 100/100 entity strength

Latest news

Evommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeatMarketBeat · Sat, 08 Aug 2026 08:35:28 GMTRBC Adjusts PT on Evommune to $29 From $30, Maintains Outperform Speculative Risk Rating - marketscreener.commarketscreener.com · Fri, 07 Aug 2026 12:55:38 GMTEvommune reports Q2 2026 net loss of $32.2M, cash $288.0M; EVO756 Phase 2b AD readout due Sept 2026 - TradingViewTradingView · Thu, 06 Aug 2026 20:13:22 GMTEvommune, Inc. 2Q 2026: Revenue $0 Net loss $53.9M — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:11:01 GMTEvommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Business WireBusiness Wire · Thu, 06 Aug 2026 20:05:00 GMTEvommune Doses First Patient in Migraine Trial - NewsBreak: Local News & AlertsNewsBreak: Local News & Alerts · Mon, 03 Aug 2026 23:22:04 GMTHC Wainwright Reiterates Neutral Rating for Evommune (NYSE:EVMN) - MarketBeatMarketBeat · Mon, 03 Aug 2026 12:34:44 GMTEvommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis - Business WireBusiness Wire · Thu, 30 Jul 2026 07:00:00 GMT

Timeline

Sat, 08 Aug 2026 08:35:28 GMTEvommune, Inc. (NYSE:EVMN) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Fri, 07 Aug 2026 12:55:38 GMTRBC Adjusts PT on Evommune to $29 From $30, Maintains Outperform Speculative Risk Rating - marketscreener.com
Thu, 06 Aug 2026 20:13:22 GMTEvommune reports Q2 2026 net loss of $32.2M, cash $288.0M; EVO756 Phase 2b AD readout due Sept 2026 - TradingView
Thu, 06 Aug 2026 20:11:01 GMTEvommune, Inc. 2Q 2026: Revenue $0 Net loss $53.9M — 10-Q Summary - TradingView
Thu, 06 Aug 2026 20:05:00 GMTEvommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights - Business Wire
Mon, 03 Aug 2026 23:22:04 GMTEvommune Doses First Patient in Migraine Trial - NewsBreak: Local News & Alerts

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.EconomyEconomy stories explain how money, jobs, prices, policy, trade, and business confidence affect daily life.

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Evommune Reports Second.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

5 distinct publisher/source names are currently connected to this entity page.